Itraconazole-Induced Psychosis: A Case Report

Psychiatric manifestations as side effects of antifungal therapies are rare and most often associated with second- and third-generation agents. This case report describes a rare incident of first-episode psychosis following itraconazole therapy in a male patient in his 50s with no previous psychiatric history or identifiable risk factors for psychosis. The onset of visual and auditory hallucinations, persecutory delusions, and disturbed sleep coincided with antifungal treatment for Aspergillus fumigatus infection. Physical, biochemical, and radiological investigations revealed no alternative cause for his presentation. Symptoms resolved following discontinuation of itraconazole and initiation of olanzapine, further supporting itraconazole as the likely precipitant. The patient has remained well with no recurrence of psychotic symptoms to date. Currently, only a limited number of similar cases following antifungal use have been reported in the literature, and fewer still following the specific use of itraconazole. This report aims to raise clinician awareness of this potential adverse effect to support safer antifungal prescribing, particularly for patients at higher risk of developing psychotic symptoms. Despite its rarity, increased vigilance may help prevent severe psychotic episodes in previously well individuals.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-11-19
DOI
https://doi.org/10.7759/cureus.97210
Citations
1
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
1.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Itraconazole-Induced Psychosis: A Case Report

Calvin T. Sung, Flavia Napoletano, Alexander J Skingle, W. Li
1 citations
Cureus
Antifungal resistance and susceptibility
1.40
article

Itraconazole-Induced Psychosis: A Case Report

Calvin T. Sung, Flavia Napoletano, Alexander J Skingle, W. Li
article en
1 citations

Abstract

Psychiatric manifestations as side effects of antifungal therapies are rare and most often associated with second- and third-generation agents. This case report describes a rare incident of first-episode psychosis following itraconazole therapy in a male patient in his 50s with no previous psychiatric history or identifiable risk factors for psychosis. The onset of visual and auditory hallucinations, persecutory delusions, and disturbed sleep coincided with antifungal treatment for Aspergillus fumigatus infection. Physical, biochemical, and radiological investigations revealed no alternative cause for his presentation. Symptoms resolved following discontinuation of itraconazole and initiation of olanzapine, further supporting itraconazole as the likely precipitant. The patient has remained well with no recurrence of psychotic symptoms to date. Currently, only a limited number of similar cases following antifungal use have been reported in the literature, and fewer still following the specific use of itraconazole. This report aims to raise clinician awareness of this potential adverse effect to support safer antifungal prescribing, particularly for patients at higher risk of developing psychotic symptoms. Despite its rarity, increased vigilance may help prevent severe psychotic episodes in previously well individuals.

CureusVol. 17(11)
Queen Mary University of London (GB), East London NHS Foundation Trust (GB), East Suffolk and North Essex NHS Foundation Trust (GB)
Openalex Percentile: Top 14%
Antifungal resistance and susceptibility
1.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.